Survival of Living-Related Kidney Graft Recipients in the Era of Modern Immunosuppressive Treatment
| Autor: | Goran Imamović, Enver Zerem, Enes Osmanovic |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Adult Graft Rejection Male medicine.medical_specialty lcsh:Medicine Cohort Studies Young Adult Internal medicine Allograft survival medicine Living Donors Humans Hospitals Teaching Kidney transplantation Retrospective Studies Immunosuppressive treatment Kidney business.industry Graft Survival lcsh:R General Medicine medicine.disease Kidney Transplantation Surgery Survival Rate surgical procedures operative medicine.anatomical_structure Drug Therapy Combination Female Original Article business Immunosuppressive Agents |
| Zdroj: | Annals of Saudi Medicine, Vol 31, Iss 3, Pp 279-283 (2011) Annals of Saudi Medicine |
| ISSN: | 0975-4466 0256-4947 |
| Popis: | Background and Objectives: Currently, there is no consensus about immunosuppressive therapy following kidney transplantation. Acute rejection rates and allograft survival rates are the clinical outcomes traditionally used to compare the efficacy of various immunosuppressive regimens. Therefore, we conducted this study to evaluate whether patient survival rates improved in the era of modern immunosuppressive treatment during living-related kidney transplantation. Design and Setting: Retrospective cohort study in a university-based tertiary internal medicine teaching hospital performed between 1999 and 2009 and patients followed up to 7 years. Patients and Methods: Survival rates were assessed in 38 patients receiving basiliximab and mycophenolate mofetil (regimen A) and 32 patients receiving antithymocyte globulin and azathioprine (regimen B). The rest of the regimen (cyclosporine A and steroids) remained the same. A secondary end point was acute rejection episode. Results: Seven-year survival rates were 100% and 72% (P=.001) and 7-year acute rejection-free survival rates were 82% and 53% (P=.03), in groups A and B, respectively. Conclusion: Long-term survival after living-related kidney transplantation has improved in the era of modern immunosuppressive treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|